The aim of the study was to determine whether zileuton, an inhibitor of 5-lipoxygenase, attenuated bronchial hyperresponsiveness (BHR) in asthmatic subjects who had marked BHR during maintenance treatment with inhaled cor ticosteroids (ICS).
Current therapy for asthma is aimed at suppressing the inflammatory process in the wall of the airways, thus reducing symptoms of bronchial hyperresponsive ness (BHR) and airways obstruction. Inhaled corticos teroids (ICS) have been shown to be very effective in this respect. This may result in a tendency towards pre scribing high doses for prolonged periods of time. In this respect, concerns about the safety of ICS have recently been addressed [1» 2]. ICS may reduce serum cortisol levels, alter biochemical markers of bone metabolism, and, in children, suppress growth velocity. The long term clinical significance o f these changes is not yet clear.
Other classes of anti-inflammatory agents for the treat ment of asthma are currently under investigation. One of these drugs, zileuton (AM~(benzo(/?)thien-2-ylethyl)-N-hydroxyurea), an inhibitor of the 5-lipoxygenase pathway, has been shown to be efficacious in patients with asthma [3-6]. Single-dose studies have shown an attenuation of the asthmatic response to cold dry air [7], but not after allergen challenge [8], In aspirin-sensitive For editorial comment see page 2701 asthmatics, 2.4 mg zileuton daily for 1 week prevented the fall in forced expiratory volume in one second (FEV i) in response to ingestion of aspirin [9] . A similar dose, administered for 2 days, attenuated exercise-induced bronchoconstriction [10], A 13 week treatment period with zileuton, 1.6 or 2.4 mg daily, resulted in a 58% increase in the cold air minute ventilation required to cause a 15% decrease in FEVi [11] . Asthma symptoms and FEVi improved after 4 [12] to 13 weeks [13] of treatment with a similar dose of zileuton, without clear side-effects [12], Whether zileuton has an additional effect on BHR in patients already treated with ICS is unknown. Such an action would be of potential clinical relevance, since it would allow tapering of the dosage of ICS. In the pre sent study, this question was addressed by measuring the effect of a single dose of 400 mg zileuton during chal lenge with histamine (which, in the main, acts directly on airway smooth muscle) and ultrason ically-nebulized distilled water (UNDW) (which induces bronchocon striction by the release of several mediators) in patients with asthma who were on maintenance treatment with ICS.
Patients and methods

Study design
This study was carried out using a randomized, dou ble-blind, placebo-controlled, cross-over design. Seven patients with asthma according to the American Thor acic Society (ATS) criteria [14], who had marked BHR during treatment for at least 6 months with up to 800 jxg ICS, were studied. They were tested on four different occasions separated by at least 5 days within a period of 4 weeks. Two challenge tests with UNDW (provo cative dose of UNDW causing a 20% fall in FEVi) (PD20,UNDW)) and two with histamine (provocative concentration of histamine causing a 20% fall in FEVi (PC20,Hist)) were performed in random order 3 h after an 09:00 h dose of either zileuton or placebo.
Subjects
Nonsmoking patients with allergic asthma, who exhibited marked BHR under maintenance treatment with ICS for at least 6 months, were selected. Allergy was defined as an elevated specific immunoglobulin E (IgE) or a positive skin-prick test for house dust mite or at least two other common aeroallergens [15] Pa tients were included if their FEV l was above 70% of pred icted [16] and PD20JJNDW was below 8 mL. The second criterion was set for two reasons: firstly, from previous studies in our laboratory it appeared that this level of PD20.UNDW was associated with a PC20,Hist of less than 4 mg-mL'1 [17, 18]; and, secondly, these levels of BHR provide the opportunity for measurable improvement by the drug under investigation. The current use of ICS (beclomethasone dipropionate or budesonide, either by metered-dose inhaler (MDI) or by dry powder) was not allowed to be higher than 800 \ig daily. All sub jects used salbutamol as rescue medication. Patients on long-acting ß2-agonists, theophylline and oral anticoag ulative drugs, as well as patients who were pregnant or breast-feeding, were excluded from participation in the study.
A total number of 17 patients, fulfiling the requirements with regard to current medication, were screened to participate. Ten subjects were not enrolled into the study, since the screening UNDW challenge test appeared to be negative. By chance, the seven subjects partici pating in the study were all female. Laboratory testing (complete blood count, serum chemistry) was performed after each provocation to assess the safety and tolerability of zileuton.
Measurement o f lung function and BHR
Subjects did not use ICS or rescue medication for at least 8 h before each visit and rested 30 min before the measurements were started. Baseline FEVi on the four study days had to be within 10%, otherwise the test was postponed to a later day. Lung function and responses to provocation with histam ine and U N D W were assessed by FEV l , measured with a flow-volume curve recorded on a heated pneumotachograph (Spiro analyzer ST 250®; Fukuda Sangyo Co., Tokyo, Japan). Baseline lung function was recorded as the best of three repro ducible values of FEVi (within 5%) before the provo cation tests.
The same technician from the lung function depart ment always checked the patients morning FEV 1. If the patient fulfilled the entry criteria, the technician then delivered the correct tablet according to the random ization list. Randomization was performed in blocks of four prior to the start of the study. For each participant number a sequence of measurements with either tablet "A" of "B" was listed according to the randomization list.Thefour tests (i.e. A-Hist, A-UNDW, B-Hist,B-UNDW) were sequenced at random. The patients received oral zileuton (capsules, 400 mg) or placebo capsules of identical appearance (both supplied by Abbott Labora tories) according to a blinded and randomized code. This dose of zileuton was chosen since leukotriene B4 (LTB4) production by ex vivo calcium ionophone-stimulated whole blood from healthy volunteers was inhib ited by up to 80% of baseline. This response was studied in dosages of 200, 400, 600 and 800 mg of zileuton, and this reduction appeared to plateau at a dose of 400 mg [19]. Thus, 400 mg appeal's to be a dose that might be expected to have some physiological effect, Three hours after intake, FEVi was measured again. Subsequently, the provocation tests were performed. The histamine provocation test was carried out accord ing to the method of C ockcroft et al. [20] . For 2 min, patients inhaled doubling concentrations of histamine acid phosphate by tidal breathing, increasing from 0.03 to 16 mg-mL-1. Histamine was nebulized with a DeVilbiss 646 nebulizer (DeVilbiss, Somerset, PA, USA) with a fixed output of 0.13 mg-mL-1. PC20,Hist was determined in mg-mL-1 by interpolating the last two points of the dose-response curve on a semilogarithmic scale. Responsiveness to UNDW was assessed according to the method of G root et aL [17] . UNDW was gen erated with an ultrasonic nebulizer (Ultraneb 99; DeVilbiss, Somerset, PA, USA) at a fixed output of 2.00+0.05 mg'm L'1. After inhalation of 20 L of ambient air through the system, patients inhaled doubling volumes of air with UNDW (3, 5, 10, up to 160 L), measured with a Wright respirometer (British Oxygen Co., London, UK). The respirometer was placed between the aerosol hose and the mouthpiece by means of a two-way valve. Before and after each test, the nebulizer chamber and aerosol hose were weighed to determine the exact amount of distilled water inhaled. The cumulative amount of inhaled water (mL) causing a 20% fall in FEVi from post-air values (PD20,UNDW) was calculated by linear interpolation on a semilogarithmic curve.
Statistical analysis
PC20 and PD20 values were log transformed before analysis and compared by analysis of variance using the Statistical Package for the Social Sciences (SPSS) ver sion 5.0 software [21]. Paired data were analysed using the Wilcox on signed rank test. Carry-over effects were analysed according to Pocock [22] using the Man 11-Whitney U-test. Results are presented as means and standard errors of the means (sem). Significance was accepted at a p-value of less than 0.05.
Results
Patient characteristics are summarized in table 1. Their baseline FEVi ranged 86-134% pred. The daily use of ICS ranged 200-800 \xg daily (mean 536 jig). Under this medication all patients had marked BHR, as indicated by a mean PD20,undw of 4.74 mL at entry into the study and a mean PC20,Hist of 0.99 mg-mL'1 after placebo (fig, 1) . Zileuton was well tolerated. No haematological or biochemical changes were observed after treatment, Baseline FEVi before administration of zileuton or placebo was similar on the four occasions (table 2) . Neither zileuton nor placebo changed FEVi 3 h after intake. Thus, zileuton did not cause acute bronchodilation in these patients.
Zileuton increased PC20,Hist from 0.99 (0.29) to 5.64 (2,27) mgTnL-1 (2.1 doubling doses (DD); p<0.03 com pared to placebo) (fig, 1) , In six of the seven patients, a clear increase was observed. PD20,UNDW was increased from 3,10 (0.56) to 9.31 (3.38) mL (1.3 DD; p<0.05 compared to placebo) (fig, 2) , Again, an improvement was observed in all but one patient (which was not the same patient as the one that showed no improvement of the PC20,Hist).
To exclude some unexpected order effect, table 3 lists the individual data set out by order of challenge and drug with the gap between the challenges applied. Apparently, no order effect was present; e.g. patients who received zileuton at the last challenge (Nos, 1,3,  6 and 7) and patients who received placebo at the last challenge (Nos. 2, 4 and 5) both showed improvements in the level of hyperresponsiveness. 
Discussion
The present study shows that a single dose of 400 mg zileuton improves BHR in asthmatic patients with marked BHR under maintenance treatment with ICS, Indeed, six out of seven patients showed an increase in PC20,Hist after zileuton in comparison to placebo, and, similarly, PD20rU.NDW was improved in six of the seven patients. Neither zileuton nor placebo changed airway calibre, as indicated by no changes in FEVi during 3 h after intake.
To assess the efficacy of anti-inflammatory treatment, an indirect challenge (as with UNDW) may be of value since it mimics naturally occurring bronchoconstrictor stimuli and because it reflects the severity of asthma better than pharmacological stimuli [23, 24]. UNDW induces bronchoconstriction by cell-mediated events [24]. Challenge with UNDW may increase BHR and induce a late asthmatic response, just as occurs on exposure to allergens [25, 26] . The extent of the increase in PD20, UNDW ( 1.3 DD) in the present study was slightly less than in the study of G root et aL [27] , who found an increase of 1.8 DD after 4 weeks of beclomethasone dipropionate, 800 pg daily. This may be explained by the fact that at baseline the present patients were less responsive to UNDW, the PD20,undw being 4.74 mL (at intake) and 3.1 mL (after placebo), compared to 1.3 mL in the study by G root et aL [27] .
In contrast, inhaled histamine acts, in the main, directly on the airway smooth muscle [23] . The magnitude of increase in PC20,Hist after a single dose of 400 mg zileu ton (2.1 DD) resembles the effects of maintenance ther apy with ICS in previous studies. The average increase in PC20 ,Hist or methacholine after chronic treatment with beclomethasone dipropionate or budesonide, as recently reviewed by B arnes and P edersen [28], is about 1-2 DD.
To the best of our knowledge, no single-or multipledose studies have been performed looking directly at histamine or methacholine reactivity after the admin istration of 5-lipoxygenase inhibitors. With leukotriene receptor antagonists, a small but significant reduction (from 0,30 to 0.48 mg-mL"1) in methacholine respon siveness was observed after a 1 week treatment of asth matic patients with pranlukast [29], Therefore, the magnitude of the acute effect of zileuton on histamine and UNDW reactivity observed in the present study is difficult to compare with previous data.
The mechanisms by which zileuton attenuates the response to histamine and UNDW in these asthmatics who are being treated with ICS are unknown. Previous studies showed that a single dose of 600 mg zileuton rapidly {i.e. within 1 h) increased FEVi by -0.35 L in patients with an FEVi of ~57-60% pred [12], Such improvement was not observed in other studies [7, 8] or in the present patients, presumably because the FEVi was close to its predicted value in these studies. Thus, an increase in airway calibre is unlikely to be the expla nation for the reduced responses to histamine and UNDW challenge after zileuton found in the present study.
Other mechanisms may be considered to explain the observed additive effect of zileuton on BHR, besides ICS, although we did not attempt to explore these possi bilities. It might be postulated that zileuton has, besides ICS, an additional inhibitory effect on the activation of the 5-lipoxygenase pathway. Such action would ex plain the increase in PD20,UNDW by an inhibitory action 011 leukotriene (LT)C4, LTD4 and LTE4 production in duced by osmolar changes. Indeed, UNDW appears to induce leukotriene production. M eslier et aL [30] showed that intranasal installation of distilled water aerosol in responsive subjects with allergic rhinitis raised the humoral and cellular content of nasal lavage fluid, in cluding LTB4 and LTD4, to a similar extent as after al lergen challenge. In contrast, there is no evidence that post-histamine-induced responses might be mediated by leukotrienes. Histamine provocation did not prov oke release of leukotrienes [31]. Nevertheless, it cannot be excluded that patients with still significant BHR des pite ICS are those in whom bronchoconstriction is, in part, dependent on leukotrienes. Another potential explanation is that zileuton might act, in part, as an antihistamine. This could explain the effects on hista mine reactivity as well as a smaller effect on UNDW, However, to our knowledge pharmacological data to support this concept are not available. Clearly, sub sequent studies are required to explore the above-mentioned possibilities.
Finally, a potential order effect associated with tachy phylaxis should be considered. In this study, measure ments were performed with an interval of at least 5 days. This study design was chosen since it is known that histamine provocation may induce a significant bron choconstriction response to UNDW [17]. Tachyphylaxis for repeated histamine provocations may exist, as does refractoriness for UNDW, which may persist up to 4 h [17]. The half-life of zileuton is 2.5 h, and its effect on 5-lipoxygenase activity should have been dissipated less than 16 h postingestion [11] . Looking at table 3, how ever, no order effect appeared to be present.
In conclusion, although the number of patients stud ied was small, the present data show that a single dose of 400 mg zileuton may attenuate bronchial hyperre sponsiveness in stero id-depen dent asthmatics. Additional studies are necessary to investigate whether similar effects are found after prolonged periods of treatment with zileuton.
